|Dr. Frank Litvack||Exec. Chairman||N/A||N/A||1956|
|Dr. Linda Marbán||Co-Founder, Pres, CEO & Director||232.91k||N/A||1963|
|Ms. Karen G. Krasney||Exec. VP, Gen. Counsel & Sec.||260.38k||N/A||1953|
|Dr. Deborah D. Ascheim||Chief Medical Officer||N/A||N/A||1965|
|Prof. Eduardo Marbán||Co-Founder & Chairman of Scientific Advisory Board||N/A||N/A||N/A|
Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other medical conditions. Its development stage drug candidates for cardiosphere-derived cells include CAP-1002 that is in Phase I/II clinical trial in subjects with DMD; and CAP-2003 that is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.
Capricor Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.